Novel adjuvant therapies for pancreatic adenocarcinoma

Tolutope Oyasiji; Wen Wee Ma

doi:10.3978/j.issn.2078-6891.2015.031

Novel adjuvant therapies for pancreatic adenocarcinoma

Tolutope Oyasiji, Wen Wee Ma

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

Original language	English (US)
Pages (from-to)	430-435
Number of pages	6
Journal	Journal of Gastrointestinal Oncology
Volume	6
Issue number	4
DOIs	https://doi.org/10.3978/j.issn.2078-6891.2015.031
State	Published - 2015

Keywords

Adjuvant therapy
Immunotherapy
Pancreatic cancer
Vaccines

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.3978/j.issn.2078-6891.2015.031

Cite this

@article{f3603deebfb843e2aa8e8ef0267dbef2,

title = "Novel adjuvant therapies for pancreatic adenocarcinoma",

abstract = "Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.",

keywords = "Adjuvant therapy, Immunotherapy, Pancreatic cancer, Vaccines",

author = "Tolutope Oyasiji and Ma, {Wen Wee}",

note = "Publisher Copyright: {\textcopyright} Journal of Gastrointestinal Oncology.",

year = "2015",

doi = "10.3978/j.issn.2078-6891.2015.031",

language = "English (US)",

volume = "6",

pages = "430--435",

journal = "Journal of Gastrointestinal Oncology",

issn = "2078-6891",

publisher = "Pioneer Bioscience Publishing Company (PBPC)",

number = "4",

}

TY - JOUR

T1 - Novel adjuvant therapies for pancreatic adenocarcinoma

AU - Oyasiji, Tolutope

AU - Ma, Wen Wee

N1 - Publisher Copyright: © Journal of Gastrointestinal Oncology.

PY - 2015

Y1 - 2015

N2 - Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

AB - Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

KW - Adjuvant therapy

KW - Immunotherapy

KW - Pancreatic cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84995810291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810291&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2015.031

DO - 10.3978/j.issn.2078-6891.2015.031

M3 - Review article

AN - SCOPUS:84995810291

SN - 2078-6891

VL - 6

SP - 430

EP - 435

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

IS - 4

ER -

Novel adjuvant therapies for pancreatic adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this